Skip to main content

Advertisement

SpringerLink
Log in

Treatment of poems syndrome

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

(polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) syndrome is a rare multisystemic paraneoplastic syndrome driven by an underlying plasma cell dyscrasia. More than 95% of patients will have monoclonal lambda sclerotic plasmacytoma( s) or bone marrow infiltration. Recognition of the complex of a combination of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes, sclerotic bone lesions, Castleman disease, thrombocytosis, papilledema, peripheral edema, pleural effusions, ascites, fingernail clubbing, and white nails is the first step in effectively managing the disease. Once a patient has been completely evaluated, each component of the disease should be addressed, while finalizing a treatment plan for the underlying plasma cell proliferative disorder. In patients with a dominant sclerotic plasmacytoma, first-line therapy should include radiation to the lesion. Retrospective analysis and personal experience would dictate that systemic therapy be considered for patients with diffuse sclerotic lesions or absence of any bone lesion and for patients who have not demonstrated stabilization of their disease 3 to 6 months after completing radiation therapy. Treatments with demonstrated benefit include corticosteroids, low-dose alkylator therapy, and high-dose chemotherapy with peripheral blood stem cell transplant. Until the pathogenesis is fully understood, these are the mainstays of treatment for patients with POEMS syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Bardwick PA, Zvaifler NJ, Gill GN, et al.: Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine 1980, 59:311–322. Authors introduce two new cases and review the literature, but devise the acronym POEMS to refer to the syndrome.

    Article  PubMed  CAS  Google Scholar 

  2. Nakanishi T, Sobue I, Toyokura Y, et al.: The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology 1984, 34:712–720. The largest English language report of the syndrome from Japan (102 patients from a nationwide survey and review of the Japanese literature). The paper emphasizes that the syndrome may exist in the absence of bone lesions, may be associated with Castleman disease, and monoclonal kappa plasma cell clones are rare.

    PubMed  CAS  Google Scholar 

  3. Driedger H, Pruzanski W: Plasma cell neoplasia with peripheral polyneuropathy. A study of five cases and a review of the literature. Medicine 1980, 59:301–310.

    Article  PubMed  CAS  Google Scholar 

  4. Soubrier MJ, Dubost JJ, Sauvezie BJ: POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. Am J Med 1994, 97:543–553. A report of 25 patients from France with an extensive review of the literature incorporating 114 non-Asian cases derived from 76 reports, in addition to the 102 cases in Japan reported by Nakanishi et al. [2•].

    Article  PubMed  CAS  Google Scholar 

  5. Dispenzieri A, Kyle RA, Lacy MQ, et al.: POEMS syndrome: definitions and long-term outcome. Blood 2003, 101:2496–2506. This paper involves the largest series (99 patients) from a single institution. It sets forth diagnostic criteria for the diagnosis. The paper emphasizes that the long-term outcome for patients is good, the number of POEMS features is not prognostic, patients can acquire additional features over time, and pulmonary hypertension and congestive heart failure may be part of the syndrome. The authors demonstrate that fingernail clubbing and extravascular volume overload are the presenting features most predictive of survival.

    Article  PubMed  CAS  Google Scholar 

  6. Hashiguchi T, Arimura K, Matsumuro K, et al.: Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome. Muscle Nerve 2000, 23:1051–1056.

    Article  PubMed  CAS  Google Scholar 

  7. Watanabe O, Maruyama I, Arimura K, et al.: Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 1998, 21:1390–1397. Authors make a convincing case that the overproduction of VEGF/vascular permeability factor is important in the pathogenesis of this disorder. They examined the levels of the VEGF in the serum and cerebrospinal fluid from 10 patients with this syndrome and demonstrated that serum VEGF levels were approximately 15 to 30 times greater than serum levels in controls.

    Article  PubMed  CAS  Google Scholar 

  8. Morley JB, Schwieger AC: The relation between chronic polyneuropathy and osteosclerotic myeloma. J Neurol Neurosurg Psychiatry 1967, 30:432–442.

    PubMed  CAS  Google Scholar 

  9. Davis L, Drachman D: Myeloma neuropathy. Successful treatment of two patients and review of cases. Arch Neurol 1972, 27:507–511.

    PubMed  CAS  Google Scholar 

  10. Iwashita H, Ohnishi A, Asada M, et al.: Polyneuropathy, skin hyperpigmentation, edema, and hypertrichosis in localized osteosclerotic myeloma. Neurology 1977, 27:675–681. One of the early articles defining the paraneoplastic syndrome referred to as POEMS.

    PubMed  CAS  Google Scholar 

  11. Dispenzieri A, Moreno-Aspitia A, Lacy MQ, et al.: Peripheral blood stem cell transplant (PBSCT) in a large series of patients with POEMS syndrome. Biol Blood Marrow Transplant 2004, 10:14–15.

    Article  Google Scholar 

  12. Hogan WJ, Lacy MQ, Wiseman GA, et al.: Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation. Bone Marrow Transplant 2001, 28:305–309. First report of a successful peripheral blood stem cell transplant in a patient with POEMS.

    Article  PubMed  CAS  Google Scholar 

  13. Rovira M, Carreras E, Blade J, et al.: Dramatic improvement of POEMS syndrome following autologous haematopoietic cell transplantation. Br J Haematol 2001, 115:373–375.

    Article  PubMed  CAS  Google Scholar 

  14. Jaccard A, Royer B, Bordessoule D, et al.: High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome. Blood 2002, 99:3057–3059. Largest published series of patients with POEMS who were treated with peripheral blood stem cell transplant.

    Article  PubMed  CAS  Google Scholar 

  15. Peggs KS, Paneesha S, Kottaridis PD, et al.: Peripheral blood stem cell transplantation for POEMS syndrome. Bone Marrow Transplant 2002, 30:401–404.

    Article  PubMed  CAS  Google Scholar 

  16. Soubrier M, Ruivard M, Dubost JJ, et al.: Successful use of autologous bone marrow transplantation in treating a patient with POEMS syndrome. Bone Marrow Transplant 2002, 30:61–62.

    Article  PubMed  CAS  Google Scholar 

  17. Wiesmann A, Weissert R, Kanz L, Einsele H: Long-term follow-up on a patient with incomplete POEMS syndrome undergoing high-dose therapy and autologous blood stem cell transplantation. Blood 2002, 100:2679–2680.

    Article  PubMed  CAS  Google Scholar 

  18. Barrier JH, Le Noan H, Mussini JM, Brisseau JM: Stabilisation of a severe case of P.O.E.M.S. syndrome after tamoxifen administration [letter]. J Neurol Neurosurg Psychiatry 1989, 52:286.

    PubMed  CAS  Google Scholar 

  19. Enevoldson TP, Harding AE: Improvement in the POEMS syndrome after administration of tamoxifen [letter]. J Neurol Neurosurg Psychiatry 1992, 55:71–72.

    PubMed  CAS  Google Scholar 

  20. Coto V, Auletta M, Oliviero U, et al.: POEMS syndrome: an Italian case with diagnostic and therapeutic implications. Ann Ital Med Int 1991, 6:416–419.

    PubMed  CAS  Google Scholar 

  21. Arima F, Dohmen K, Yamano Y, et al.: [Five cases of Crow-Fukase syndrome]. Fukuoka Igaku Zasshi 1992, 83:112–120.

    PubMed  CAS  Google Scholar 

  22. Authier FJ, Belec L, Levy Y, et al.: All-trans-retinoic acid in POEMS syndrome. Therapeutic effect associated with decreased circulating levels of proinflammatory cytokines. Arthritis Rheum 1996, 39:1423–1426.

    Article  PubMed  CAS  Google Scholar 

  23. Orefice G, Morra VB, De Michele G, et al.: POEMS syndrome: clinical, pathological, and immunological study of a case. Neurol Res 1994, 16:477–480.

    PubMed  CAS  Google Scholar 

  24. Sano M, Terasaki T, Koyama A, et al.: Glomerular lesions associated with the Crow-Fukase syndrome. Virchows Arch A Pathol Anat Histopathol 1986, 409:3–9.

    Article  PubMed  CAS  Google Scholar 

  25. Henze T, Krieger G: Combined high-dose 7S-IgG and dexamethasone is effective in severe polyneuropathy of the POEMS syndrome [letter]. J Neurol 1995, 242:482–483.

    Article  PubMed  CAS  Google Scholar 

  26. Rotta FT, Bradley WG: Marked improvement of severe polyneuropathy associated with multifocal osteosclerotic myeloma following surgery, radiation, and chemotherapy. Muscle Nerve 1997, 20:1035–1037.

    Article  PubMed  CAS  Google Scholar 

  27. Atsumi T, Kato K, Kurosawa S, et al.: A case of Crow-Fukase syndrome with elevated soluble interleukin-6 receptor in cerebrospinal fluid. Response to doublefiltration plasmapheresis and corticosteroids. Acta Haematol 1995, 94:90–94.

    PubMed  CAS  Google Scholar 

  28. Kuwabara S, Hattori T, Shimoe Y, Kamitsukasa I: Longterm melphalan-prednisolone chemotherapy for POEMS syndrome. J Neurol Neurosurg Psychiatry 1997, 63:385–387.

    Article  PubMed  CAS  Google Scholar 

  29. Stewart PM, McIntyre MA, Edwards CR: The endocrinopathy of POEMS syndrome. Scott Med J 1989, 34:520–522.

    PubMed  CAS  Google Scholar 

  30. Reulecke M, Dumas M, Meier C: Specific antibody activity against neuroendocrine tissue in a case of POEMS syndrome with IgG gammopathy. Neurology 1988, 38:614–616.

    PubMed  CAS  Google Scholar 

  31. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. Myeloma Trialists’ Collaborative Group. J Clin Oncol 1998, 16:3832–3842.

  32. Satoh K, Miura I, Chubachi A, et al.: Development of secondary leukemia associated with (1;7)(q10;p10) in a patient with Crow-Fukase syndrome. Intern Med 1996, 35:660–662.

    PubMed  CAS  Google Scholar 

  33. Reitan JB, Pape E, Fossa SD, et al.: Osteosclerotic myeloma with polyneuropathy. Acta Med Scand 1980, 208:137–144.

    Article  PubMed  CAS  Google Scholar 

  34. Ku A, Lachmann E, Tunkel R, Nagler W: Severe polyneuropathy: initial manifestation of Castleman’s disease associated with POEMS syndrome. Arch Phys Med Rehabil 1995, 76:692–694.

    Article  PubMed  CAS  Google Scholar 

  35. Cabezas-Agricola JM, Lado-Abeal JJ, Otero-Anton E, et al.: Hypoparathyroidism in POEMS syndrome [letter]. Lancet 1996, 347:701–702.

    Article  PubMed  CAS  Google Scholar 

  36. Crisci C, Barbieri F, Parente D, et al.: POEMS syndrome: follow-up study of a case. Clin Neurol Neurosurg 1992, 94:65–68.

    Article  PubMed  CAS  Google Scholar 

  37. Takatsuki K, Sanada I: Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases. Jpn J Clin Oncol 1983, 13:543–555.

    PubMed  CAS  Google Scholar 

  38. Benito-Leon J, Lopez-Rios F, Rodriguez-Martin FJ, et al.: Rapidly deteriorating polyneuropathy associated with osteosclerotic myeloma responsive to intravenous immunoglobulin and radiotherapy. J Neurol Sci 1998, 158:113–117.

    Article  PubMed  CAS  Google Scholar 

  39. Frassica DA, Frassica FJ, Schray MF, et al.: Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys 1989, 16:43–48.

    PubMed  CAS  Google Scholar 

  40. Mendenhall CM, Thar TL, Million RR: Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys 1980, 6:1497–1501.

    PubMed  CAS  Google Scholar 

  41. Sternberg AJ, Davies P, Macmillan C, et al.: Strontium-89: a novel treatment for a case of osteosclerotic myeloma associated with life-threatening neuropathy. Br J Haematol 2002, 118:821–824.

    Article  PubMed  Google Scholar 

  42. Wong VA, Wade NK: POEMS syndrome: an unusual cause of bilateral optic disk swelling. Am J Ophthalmol 1998, 126:452–454.

    Article  PubMed  CAS  Google Scholar 

  43. Broussolle E, Vighetto A, Bancel B, et al.: P.O.E.M.S. syndrome with complete recovery after treatment of a solitary plasmocytoma. Clin Neurol Neurosurg 1991, 93:165–170.

    Article  PubMed  CAS  Google Scholar 

  44. Furuzono H, Moritoyo T, Yamada H, et al.: [A case of Crow-Fukase syndrome which developed seven years following myelopathy of unknown origin]. Rinsho Shinkeigaku 1993, 33:56–60.

    PubMed  CAS  Google Scholar 

  45. Chang YJ, Huang CC, Chu CC: Intravenous immunoglobulin therapy in POEMS syndrome: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 1996, 58:366–369.

    CAS  Google Scholar 

  46. Silberstein LE, Duggan D, Berkman EM: Therapeutic trial of plasma exchange in osteosclerotic myeloma associated with the POEMS syndrome. J Clin Apheresis 1985, 2:253–257.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, 55905, Rochester, MN, USA

    Angela Dispenzieri MD

Authors
  1. Angela Dispenzieri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Morie A. Gertz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dispenzieri, A., Gertz, M.A. Treatment of poems syndrome. Curr. Treat. Options in Oncol. 5, 249–257 (2004). https://doi.org/10.1007/s11864-004-0016-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-004-0016-4

Keywords

Search

Navigation